Skip to main content
SpringerLink
Log in

Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Spontaneous bacterial peritonitis (SBP) is a life-threatening complication of liver cirrhosis. Recently, rifaximin, a non-absorbable antibiotic which is used to prevent recurrent hepatic encephalopathy, has been proposed as effective prophylaxis for SBP. Here, we present an unusual case of SBP under treatment with rifaximin. A 50-year-old woman with liver cirrhosis was admitted because of tense ascites and abdominal pain. She was under long-term oral prophylaxis with rifaximin due to hepatic encephalopathy. Paracentesis revealed SBP caused by Pasteurella multocida, which was sensitive to multiple antibiotics, including rifaximin. Treatment with ceftriaxone resulted in rapid resolution of the peritonitis and restoration of the patient. Since P. multocida is usually transmitted from pets, the patient’s cat was tested and could be identified as the most likely source of infection. This case should elicit our awareness that uncommon pathogens and unusual routes of transmission may lead to SBP, despite antibacterial prophylaxis with non-absorbable antibiotics. Nevertheless, such infections may still remain sensitive to systemic therapy with conventional antibiotics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73:13–27.

    Article  CAS  PubMed  Google Scholar 

  2. Hu Y, Ren J, Zhan M, Li W, Dai H. Efficacy of rifaximin in prevention of travelers’ diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Travel Med. 2012;19:352–6.

    Article  PubMed  Google Scholar 

  3. Yun SP, Seon HG, Ok CS, Yoo KH, Kang MK, Kim WH, Kwon CI, Ko KH, Hwang SG, Park PW, Hong SP. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6:452–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37:122–8.

    Article  CAS  PubMed  Google Scholar 

  5. Hanouneh MA, Hanouneh IA, Hashash JG, Law R, Esfeh JM, Lopez R, Hazratjee N, Smith T, Zein NN. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012;46:709–15.

    Article  CAS  PubMed  Google Scholar 

  6. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28:450–5.

    Article  CAS  PubMed  Google Scholar 

  7. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut 2012;61:297–310.

    Article  CAS  PubMed  Google Scholar 

  8. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.

    Article  CAS  PubMed  Google Scholar 

  9. Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012;18:767–77.

    Article  CAS  PubMed  Google Scholar 

  10. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.

    Article  Google Scholar 

  11. Hubbert WT, Rosen MN. Pasteurella multocida infections. II. Pasteurella multocida infection in man unrelated to animal bite. Am J Public Health Nations Health. 1970;60:1109–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Fernández J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Ginès P, Arroyo V. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012;55:1551–61.

    Article  PubMed  Google Scholar 

  13. Reuken PA, Pletz MW, Baier M, Pfister W, Stallmach A, Bruns T. Emergence of spontaneous bacterial peritonitis due to enterococci—risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther. 2012;35:1199–208.

    Article  CAS  PubMed  Google Scholar 

  14. Tamaskar I, Ravakhah K. Spontaneous bacterial peritonitis with Pasteurella multocida in cirrhosis: case report and review of literature. South Med J. 2004;97:1113–5.

    Article  PubMed  Google Scholar 

  15. Sol PM, van de Kar NC, Schreuder MF. Cat induced Pasteurella multocida peritonitis in peritoneal dialysis: a case report and review of the literature. Int J Hyg Environ Health. 2013;216:211–3.

    Article  PubMed  Google Scholar 

  16. Miller MA, Blanchette R, Spigaglia P, Barbanti F, Mastrantonio P. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance. J Clin Microbiol. 2011;49:4319–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, Harel J, Simpson KW, Dogan B. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother. 2013;57:811–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, Salzer HJ, Krause R. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect. 2011;62:34–8.

    Article  PubMed  Google Scholar 

  19. Avril JL, Donnio PY, Pouedras P. Selective medium for Pasteurella multocida and its use to detect oropharyngeal carriage in pig breeders. J Clin Microbiol. 1990;28:1438–40.

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Siahanidou T, Gika G, Skiathitou AV, Oikonomopoulos T, Alexandrou-Athanassoulis H, Koutouzis EI, Syriopoulou VP. Pasteurella multocida infection in a neonate: evidence for a human-to-human horizontal transmission. Pediatr Infect Dis J. 2012;31:536–7.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Str. 25, 53129, Bonn, Germany

    P. Lutz, C. P. Strassburg & U. Spengler

  2. Institute for Medical Microbiology, Immunology and Parasitology, University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany

    M. Parcina, I. Bekeredjian-Ding & A. Hoerauf

Authors
  1. P. Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Parcina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Bekeredjian-Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Hoerauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. P. Strassburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. U. Spengler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Lutz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lutz, P., Parcina, M., Bekeredjian-Ding, I. et al. Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin. Infection 42, 175–177 (2014). https://doi.org/10.1007/s15010-013-0449-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-013-0449-4

Keywords

Search

Navigation